Zyn and the retailers who sell the product have run afoul of regulators in recent years. The FDA in April of last year warned ...
A new crop of companies is lining up to buy patient data from hospitals and sell it to those wanting to train AI or do ...
As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...
UnitedHealth's CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.
At the J.P. Morgan Health Care conference, the future outlook for GLP-1 drugs used to treat obesity was a key focus, ...
Rounds reports on the FDA banning red dye no. 3 and curbing nicotine levels; a study showing meat associated with dementia ...
Cancer deaths overall are falling, but the burden is shifting toward younger adults and women, the American Cancer Society ...
STAT spoke with researcher Carol Haywood about her new study that looked at the persistent ableism in medicine and its root ...
A new study highlights the potential of a therapeutic strategy focused on stopping or slowing Huntington's disease ...
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback